Immunoglobulin G1 [101-glycine,234-phenylalanine,235-glutamic acid,265-alanine,405-leucine,de-C-terminal-lysine], anti-(human CD3 antigen) (human-Mus musculus monoclonal IgG1-huCACAO-H101G-FEAL ?1-chain), disulfide with human-Mus musculus monoclonal IgG1-huCACAO-H101G-FEAL ?-chain, (234?226?),(237?229?)-bis(disulfide) with immunoglobulin G1 [234-phenylalanine,235-glutamic acid,265-alanine,409-arginine] anti-(human B7 homolog 4 protein) (human monoclonal IgG1-7724-084-N52S-FEAR ?1-chain) disulfide with human monoclonal IgG1-7724-084-N52S-FEAR ?-chain
Endometrial Cancer, Endometrial Neoplasm
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
44 Active assets in the Endometrial Cancer, Endometrial Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisotumab Vedotin Seagen Inc. | Phase 2 | BBB |
LENVATINIB Merck Sharp & Dohme LLC | Phase 3 | BB |
Pembrolizumab Eli Lilly and Company | Phase 3 | BB |
Carboplatin Eli Lilly and Company | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Eli Lilly and Company | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [101-glycine,234-phenylalanine,235-glutamic acid,265-alanine,405-leucine,de-C-terminal-lysine], anti-(human CD3 antigen) (human-Mus musculus monoclonal IgG1-huCACAO-H101G-FEAL ?1-chain), disulfide with human-Mus musculus monoclonal IgG1-huCACAO-H101G-FEAL ?-chain, (234?226?),(237?229?)-bis(disulfide) with immunoglobulin G1 [234-phenylalanine,235-glutamic acid,265-alanine,409-arginine] anti-(human B7 homolog 4 protein) (human monoclonal IgG1-7724-084-N52S-FEAR ?1-chain) disulfide with human monoclonal IgG1-7724-084-N52S-FEAR ?-chain is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →